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ABSTRACT
Apical membrane antigen 1 (AMA-1) is an immunogenic type 1 integral membrane protein, present in
all Plasmodium spp., that probably has a role in the initiation of the invasion process of the erythrocyte.
The DNA sequence of variable domain I of the Plasmodium vivax ama1 gene was sequenced in
Brazilian isolates obtained from thrombocytopenic patients (n = 32) and patients with normal platelet
counts (n = 22). There was a signiﬁcant negative correlation between parasite density and platelet
counts. It was concluded that there is an additional effect of sequence on platelet counts. The presence
of amino-acid residues Y193 and S210 was associated signiﬁcantly with normal platelet counts in
P. vivax malaria, independent of the level of parasitaemia (p <0.0001). These data have implications
for AMA-1-based vaccine design and suggest the possible use of this molecule as a marker of
morbidity.
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INTRODUCTION
Apical membrane antigen 1 (AMA-1) is an immu-
nogenic type 1 integral membrane protein, pres-
ent in all Plasmodium spp., with at least 16 cysteine
residues incorporated into eight intra-molecular
disulphide bonds that form the three domains of
the protein [1]. This protein is synthesised during
the last 4 h of the erythrocytic phase, when the
schizonts are already mature and segmented [2].
AMA-1 may have a role in the initiation of the
invasion process of the erythrocyte, and may be
directly responsible for reorientation of the mer-
ozoite, as well as participating in the junctional
contact between the two cells [3].
Polymorphisms occur non-randomly along the
coding region inside the ectodomain, especially in
domain I (the most polymorphic domain), sug-
gesting that this region is a major target of the
immune response [4]. As the gene for AMA-1
exhibits great sequence diversity, it is considered
to be a useful molecular marker, with many
alleles available to provide information concern-
ing parasite populations. In addition, this gene
also seems to be an important determinant of
morbidity, since a strong association between
clinical disease and residues Glu187 and Glu243 of
the Plasmodium falciparum ama-1 gene has been
reported [5].
Plasmodium vivax, although causing less mor-
tality than P. falciparum, has an enormous socio-
economic impact, particularly in South America
and Asia (http://rbm.whq.int/wmr2005/html/
exsummary-en.htm). According to the Brazilian
Ministry of Health, P. vivax was responsible for
c. 75% of the 500 000 cases of malaria reported
in Brazil during 2005. Malaria caused by P. vivax
has several clinical features, including fever,
headache, myalgia, nausea, diarrhoea, vomiting,
cough, liver and spleen enlargement, and
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haematological abnormalities, e.g., anaemia,
leukopenia, and thrombocytopenia [6]. Throm-
bocytopenia (<150 000 platelets ⁄lL) is not usu-
ally associated with disseminated intravascular
coagulation, and the platelet count typically
normalises following speciﬁc treatment [7]. The
mechanisms involved in P. vivax-related throm-
bocytopenia remain unknown. It has been
proposed that immune and biochemical mecha-
nisms, e.g., anti-platelet antibodies [8], oxidative
stress [9] and caspase-mediated death of throm-
bocytes [10], may cause structural damage and
loss of function of platelets. Ultrastructural
studies on platelets from patients with acute
P. falciparum malaria have revealed centralisation
of granules, platelet–platelet interaction, sponta-
neous aggregation and degranulation [11].
The present study sequenced the P. vivax ama-1
domain I gene (PvAMA-1) of 61 isolates of P. vivax
from symptomatic patients, and correlated the
polymorphic sites with levels of parasitaemia and
platelet counts. Two particular residues at certain
polymorphic sites were associated with normal
platelet levels, independent of high parasitaemia,
suggesting that AMA-1 is a possible marker of
morbidity in P. vivax infections.
MATERIALS AND METHODS
Study population and blood samples
This study concerned patients (mean age 37.5 ± 13.8 years)
with P. vivax malaria who were living in Cuiaba´, the capital of
Mato Grosso state, north-western Brazil, where active malaria
transmission does not occur. Samples were collected between
August 2004 and January 2006 from 61 patients who had been
infected in regions of six Brazilian states where malaria is
endemic, i.e., Acre, Amazonas, Mato Grosso, Para´, Rondoˆnia
and Roraima. The patients were unrelated, as there were no
family clusters. The patients attended the Hospital Julio Mu¨ller
of the Universidade Federal de Mato Grosso. Informed consent
was obtained from each subject before blood collection, as
speciﬁed by the Universidade Federal de Mato Grosso and
Universidade Federal de Minas Gerais Ethics Committee rules.
Venous blood (5 mL) was collected in EDTA-containing
tubes and was used to prepare thick smears for microscopy
and to extract parasite DNA. The parasite density was
quantiﬁed after examination of 200 microscopic ﬁelds at
1000· magniﬁcation under oil-immersion. Two patient groups
were deﬁned according to the level of parasitaemia: (i) 14
patients with £530 parasites ⁄ lL (mean age of 40.1 ± 15.9
years); and (ii) 42 patients with >530 parasites ⁄ lL (mean age
of 36.7 ± 13.4 years). The threshold of 530 parasites ⁄ lL was
based on the parasitaemia distribution (lower 25% percentile).
Patients were also classiﬁed according to their platelet levels,
as measured using a blood cell counter (ABX Pentra 90;
Horiba Diagnostics, Kyoto, Japan): (i) 32 thrombocytopenic
patients (mean age 35.5 ± 15.6 years) with platelet levels
<150 000 ⁄lL; and (ii) 22 patients (mean age of 39.1 ± 13.3
years) with platelet levels >150 000 ⁄ lL. Both sets of data
were available for 49 patients, and these were analysed to
evaluate the effect of parasitaemia on platelet counts. All
subjects were interviewed and examined by the same physi-
cian, and all were prescribed chloroquine and primaquine in
agreement with the Brazilian national policy for the treatment
of malaria.
PvAMA-1 nested PCR and sequencing
Nested PCR was performed with DNA extracted from blood
samples using a Purogene Genomic DNA Puriﬁcation Kit
(Gentra Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions. PvAMA-1 was ampliﬁed as
described previously [12], using primers PvAR11 (5¢-CCTAA-
ATTTTTACGGGGGCA) and PvAF11 (5¢-AGAATTCCAGCT-
CCAAGATG) for the ﬁrst round of ampliﬁcation, and primers
PvAR11 and PvAF05 (5¢-TATCGTCATAGAGAATTCCG) for
the second round. PvAMA-1 PCR products from each sample
were puriﬁed using polyethylene glycol 8000 (PEG 8000) 20%
w ⁄v, and were then sequenced at least twice, using different
AMA-1 products from different PCRs. The sequences were
obtained using forward (PvAF05) and reverse (PvAR11)
primers with a DYEnamic ET Dye Terminator Kit (Amersham
Biosciences, Little Chalfont, UK) and a MegaBACE 1000
sequencing system (Amersham Biosciences). The quality of
the sequences was veriﬁed using Phred [13], Phrap [14] and
Consed [15] software. The sequences were edited using the
Mega 3.1 program [16]; the same software was also used to
calculate the genetic and nucleotide diversity of the sequences.
The sequences were aligned using ClustalW software [17]. For
haplotype generation, DNAsp 4.0 software [18] was used. As a
reference standard, the sequences were compared to those for
PH-84 (GenBank accession no. L27503).
Statistical analysis
STATA v.6.0 software (Stata Corp., College Station, TX,
USA) was used to test the association between the PvAMA-1
polymorphisms and the morbidity parameters, i.e., level of
parasitaemia and platelet levels. The two-tailed Fisher’s
exact test was used to compare all the frequencies of
particular residues at polymorphic sites with levels of
parasitaemia and platelet counts, and Bonferroni’s correction
was used for multiple testing when appropriate. Associa-
tions were detected by considering 26 independent tests,
which were considered sufﬁcient to conﬁrm that any
association was highly unlikely to have arisen by chance.
The Mann–Whitney (Wilcoxon rank sum) test and Spear-
man’s correlation coefﬁcient were used to test the depen-
dence between platelets and parasitaemia. A multiple linear
regression model was created to test the independent
contributions of parasitaemia and particular polymorphic
amino-acid residues on the platelet blood levels. Signiﬁcance
was set at the 5% level.
Nucleotide sequence accession number
Nucleotide sequences described in this report have been
submitted to GenBank under accession numbers EF031154–
EF031216 and EF057487.
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RESULTS
Amino-acid sequences and polymorphic sites
Sixty-one PvAMA-1 sequences were obtained,
and these corresponded to nucleotides 319–696
of the PH-84 isolate, which encode amino-acids
103–236. Twenty polymorphic nucleotide sites
were found, including one that was previously
unreported: a non-synonymous substitution
(A ﬁ T) at position 333, changing amino-acid
111 from Leu to Thr. The linkage disequilibrium
between amino-acid sites 227 and 228 has been
described previously [12], but another linkage
disequilibrium was found between amino-acid
sites 193 and 210 (r2 1.00) among Brazilian
samples. It was possible to distinguish 16 haplo-
types (Table 1). The genetic diversity was
0.907 ± 0.021 and the nucleotide diversity was
0.017 ± 0.009.
Association between the level of parasitaemia
and platelet blood counts
The median level of parasitaemia among the
thrombocytopenic patients (platelet counts
<150 000 ⁄ lL) was 1850 parasites ⁄ lL, which was
higher than the median level among non-throm-
bocytopenic patients (560 parasites ⁄ lL). A signif-
icant negative correlation (r 0.42; p 0.003)
between the platelet counts and the level of
parasitaemia was detected (Fig. 1), but there was
no signiﬁcant association between a patient’s age
and the level of parasitaemia or platelet counts
(data not shown).
Association between polymorphisms at
particular amino-acid sites and platelet counts
A strong association was found between amino-
acid residues Y193 ⁄ S210 and normal platelet counts
(p 0.0003), conﬁrmed by Bonferroni’s correction
for 26 independent tests (p <0.002) (Table 2). All
Brazilian samples with residues Y193 ⁄ S210 had
normal platelet counts (>150 000 platelets ⁄ lL).
After adjusting for a parasitaemia effect using a
linear regression model, a signiﬁcant association
remained between platelet counts and Y193 ⁄ S210
polymorphic sites (b = 43 637; 95% CI 9439–
77 836, p 0.001) (Table 2). Moreover, the median
level of parasitaemia was lower with amino-acid
residues Y193 ⁄ S210 (477; Q1–Q3 221–1134 para-
sites ⁄ lL) than with amino-acid residues
H193 ⁄ S210 (996; Q1–Q3 592–2575 parasites ⁄ lL)
(Fig. 2). With respect to median platelet counts,
samples with amino-acid residues H193 ⁄P210 had
lower counts (107 000; Q1–Q3 77 500–
157 000 platelets ⁄lL) than those with Y193 ⁄ S210
(173 500; Q1–Q3 160 000–182 000 platelets ⁄ lL)
(p 0.008) (Fig. 2).
DISCUSSION
This study revealed an association between
PvAMA-1 diversity and platelet counts among
Brazilian patients with P. vivax infections. The
analysis was restricted to ectodomain I, which is
the most polymorphic region of the molecule.
Sequence analysis revealed that Brazilian isolates
have a previously unreported polymorphism
involving a non-synonymous substitution at
Table 1. Amino-acid polymorphisms in 61 apical mem-
brane antigen 1 (AMA-1) domain I sequences
Haplotypes
Amino-acid polymorphic sites
107 111 112 120 130 132 140 141 145 189 190 193 ⁄ 210 227 ⁄ 228
H1 (13) A L T R N N L E A K Q H ⁄P E ⁄ S
H2 (11) A L T R K D L A E E K H ⁄P E ⁄ S
H3 (9) D L T R K D L E A N K H ⁄P E ⁄ S
H4 (6) D L R K N N I A A E K H ⁄P E ⁄ S
H5 (4) A L T R K D L E A E K Y ⁄ S E ⁄ S
H6 (3) A L T R K D L A A E K Y ⁄ S E ⁄ S
H7 (3) A L T R N N L E A E K H ⁄P E ⁄ S
H8 (2) A L T R N N I A A E K H ⁄P E ⁄ S
H9 (2) D L R K N N I A A E K H ⁄P V ⁄D
H10 (2) D F K R N N I A A E K H ⁄P E ⁄ S
H11 (1) A F T R N N L E A K Q H ⁄P E ⁄ S
H12 (1) A L T R N N I A A E Q H ⁄P E ⁄ S
H13 (1) A L K R N N I A E E K H ⁄P E ⁄ S
H14 (1) D L K R N N I A A E K H ⁄P E ⁄ S
H15 (1) D L T R K D L E A N K H ⁄P E ⁄ S
H16 (1) A L T R N D L A A E K Y ⁄ S E ⁄ S
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Fig. 1. Correlation between platelet counts and the degree
of parasitaemia among 49 patients with Plasmodium vivax
malaria.
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amino-acid site 111, with the presence of nucleo-
tide T333 instead of A333 changing the amino-acid
translation from L111 to T111.
It has been observed previously that the major-
ity of patients infected by either P. falciparum or
P. vivax develop thrombocytopenia during acute
malaria [7]. Previous studies have failed to show a
correlation between the level of parasitaemia and
platelet counts in patients with acute P. falciparum
and P. vivax infection [11,19,20]. However, the
present study found that normal platelet counts
correlated strongly with low levels of P. vivax
parasitaemia. It is not clear why certain P. vivax
infections might cause a decrease in the number
of platelets while others do not, but there is
evidence that host factors are involved [8]. It is
accepted that the immune system has an impor-
tant role through the binding of IgG to platelet-
associated malarial antigen. Speciﬁc IgG could
bind through the Fab terminus to platelet-bound
malarial antigen, leading to phagocytosis by
macrophages or monocytes [8]. This potential
mechanism stimulated the present investigation
of a possible association between polymorphism
of the malarial vaccine candidate AMA-1 and
P. vivax-related thrombocytopenia.
AMA-1 is a major target of the immune system,
inducing an antibody-dependent immune re-
sponse. AMA-1 is synthesised late in the
development of parasite schizonts as an 83-kDa
precursor, which is located initially in the micro-
nemes of the apical complex of merozoites, and is
processed proteolytically before its re-location to
the surface of the mature merozoites [21]. Once on
the surface, this form is redistributed and under-
goes two C-terminal cleavages, after which the
fragments are shed from the parasite surface as
soluble forms, with or without domain III [22].
Table 2. Associations between amino-acid polymorphic
sites and levels of parasitaemia and platelet counts among
Brazilian patients with Plasmodium vivax malaria
Position
(amino-acid)
Parasitaemia (n = 56) Platelet count (n = 54)
No. of sequences with
the indicated amino-acid
No. of sequences with
the indicated amino-acid
<530 ⁄ lL
(n = 14)
>530 ⁄ lL
(n = 42) pa
<150 000 ⁄ lL
(n = 32)
>150 000 ⁄ lL
(n = 22) pa pb
107
A 11 26 0.337 21 15 1.000
D 3 16 11 7
111
F 1 1 0.440 1 2 0.562
L 13 41 31 20
112
K 0 3 0.257 3 1 0.171
R 1 7 6 1
T 13 32 23 20
120
K 1 17 0.663 6 1 0.220
R 13 35 26 21
130
K 10 16 0.061 11 14 0.052
N 4 26 21 8
132
D 10 17 0.064 11 15 0.025
N 4 25 21 7
140
I 1 13 0.150 10 3 0.198
L 13 29 22 19
141
A 7 19 0.767 18 9 0.406
E 7 23 14 14
145
A 11 34 1.000 23 20 0.167
E 3 8 9 2
189
E 9 25 1.000 20 14 1.000
K 3 10 9 3
N 2 7 3 5
190
K 11 31 1.000 22 19 0.198
Q 3 11 10 3
193 ⁄ 210
H ⁄P 11 37 0.398 32 14 0.000c 0.001
Y ⁄ S 3 5 0 8
227 ⁄ 228
E ⁄ S 12 34 1.000 27 18 1.000
V ⁄D 2 8 5 4
aFisher’s exact test.
bMultivariate linear regression analysis to evaluate the independent contribution of
the presence of particular amino-acid residues at polymorphic sites 193 and 210 and
the level of parasitaemia to platelet counts.
cp <0.008 after Bonferroni’s correction.
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Fig. 2. Median (a) levels of parasitaemia and (b) platelet
counts according to the presence of particular amino-acid
residues at polymorphic sites 193 ⁄ 210 among subjects with
symptomatic Plasmodium vivax infections. The Mann–
Whitney test was used to compare the levels of parasita-
emia and platelet counts among samples.
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Thus, it can be expected that binding of AMA-
1-released domains on the platelet surface, and
subsequent formation of AMA-1–IgG immune
complexes, may contribute to the structural and
functional abnormalities of platelets [11].
The presence of Y193 ⁄ S210 was associated with
normal platelet counts, independent of the effect
of parasitaemia. These amino-acid residues are in
linkage disequilibrium in Brazil, although this is
not apparent in sequences reported previously
[12]. However, it is not possible to determine
which amino-acid, Y193 or S210, is associated with
an absence of thrombocytopenia, or whether both
are. Indeed, it is also difﬁcult to investigate a
possible direct effect of particular residues on
P. vivax-related thrombocytopenia, since their
combination with other residues from different
malarial antigens may contribute to this clinical
feature.
The present study revealed an association
between thrombocytopenia and particular amino-
acid substitutions. A strain-speciﬁc mechanism
that may explain the thrombocytopenia associ-
ated with vivax malaria is that the polymorphic
residues Y193 ⁄ S210 decrease the immunogenicity
of PvAMA-1 and, consequently, the antibody
response against these forms of PvAMA-1
would be less pronounced. A reduction in the
antibody response would lead to reduced for-
mation of immunocomplexes and, consequently,
fewer platelets would be destroyed by phago-
cytosis. In contrast, patients infected with par-
asites with the polymorphic residues H193 ⁄P210
would have a stronger antibody response, gen-
erating more immunocomplexes on the platelet
surface, leading to enhanced platelet destruction
(and thrombocytopenia) by phagocytic cells
following competitive displacement of antibody
binding by increasing concentrations of malaria
antigens. This explanation is supported by the
fact that single amino-acid substitutions at the
most highly polymorphic site in the P. falciparum
AMA-1 N-terminal to C217 (residue 197) abolish
MAb 1F9 binding [23], suggesting that the
cluster of sequence polymorphisms in domain
I of AMA-1 have been selected by protective
antibody responses.
In conclusion, this is the ﬁrst study to demon-
strate the possible role of parasite polymorphism
in causing thrombocytopenia during acute
P. vivax infection. Particular amino-acid substitu-
tions in two polymorphic sites within domain I of
AMA-1 were associated with protection against
thrombocytopenia, which is an important param-
eter of morbidity during the acute infection.
Additional studies are required to fully characte-
rise the relationship between these particular
amino-acid substitutions and P. vivax-related
thrombocytopenia.
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